Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in, we provide an overview of our efforts to develop clinically translatable PD-L1-specific imaging agents for quantitative and real-time assessment of PD-L1 expression in tumor microenvironment.
Immunotherapy is emerging as an important treatment modality for various cancers. 1 Using this approach, cancer is treated by augmenting or generating an immune response against tumor cells. Tumor cells escape from immune response by deploying immunosuppressive mechanisms such as immune checkpoints. 2 These ligand-receptor interaction-mediated checkpoints modulate the amplitude and duration of immune response and act as a natural "brake" of the immune system to maintain self-tolerance. Targeting and modulating the immune checkpoint proteins by antibodies has become a powerful therapeutic strategy for anticancer immunotherapy. A major therapeutic target is the immune checkpoint axis of programmed death receptor 1 (PD-1 and CD279) and its ligand PD-L1 (B7-H1 and CD274). In a number of cancers including melanoma, renal cell carcinoma (RCC), lung, breast, ovarian, and colorectal cancers, PD-L1 expression has been shown to be upregulated constitutively 3 or due to inflammation in the tumor microenvironment (TME), leading to deactivation of PD-1-expressing tumor-infiltrating lymphocytes (TILs) that results in immune suppression. 2 Cancer treatments targeting immune checkpoints have shown robust and durable clinical responses that lead to longterm survival in some patients. 2 Several immune checkpoint targeting antibody therapeutics have received Food and Drug Administration approval. PD-L1 targeting antibodies such as MPDL3280A (atezolizumab), MEDI4736 (durvalumab), and Avelumab have demonstrated anticancer activity in multiple tumor types including advanced melanoma, 4 non-small-cell lung cancer (NSCLC), 5 RCC, 6 and bladder cancer. 7 Nearly 70% of patients with cancer do not respond to checkpoint blockade therapies, however. There is a pressing clinical need to accurately predict which patients are more likely to benefit from immunotherapy.
Methods of monitoring conventional cancer therapy can be confounding to measure immunotherapy response. For example, tumor shrinkage is initially observed in only *10% patients with immunotherapy but is a typical positive response with cytotoxic therapy. Delayed response to therapy following initial increase in tumor burden is also observed in some patients, indicative of immune-mediated response. Concurrently, it is known from biopsy specimens of tumors from patients undergoing immune checkpoint therapy that PD-L1 expression within the TME is relevant to achievement of response. 8 Currently, PD-L1 expression in the tumors is evaluated by immunohistochemistry (IHC). Food and Drug Administration has recently approved 2 IHC companion diagnostic tests (PD-L1 IHC 22C3 pharmDx and PD-L1 IHC 28-8 pharmDx). However, PD-L1 IHC has considerable inadequacies such as variable criteria for quantification, different antibodies for detection, variability in tissue preparation and processing, and heterogeneity of PD-L1 expression in primary tumors and in metastatic lesions. Also, it is impractical to perform repeated biopsy to monitor therapy response. Moreover, these limitations are compounded in patients with advanced stage disease. Thus, we hypothesized that noninvasive imaging could be a complementary and superior tool to determine in vivo PD-L1 expression in all the lesions in entirety, providing more accurate assessment of PD-L1 for therapy management.
For noninvasive detection of PD-L1, we chose atezolizumab from Genentech (San Francisco, CA) due to its extensive clinical use in cancer immunotherapy. Atezolizumab is an effector function deficient humanized immunoglobulin G1 (IgG1) monoclonal antibody with impaired binding to Fcg receptor that minimizes depletion of PD-L1-positive tumor-specific T cells. Atezolizumab has high binding affinity toward human 7, 9 thus providing an opportunity to relate preclinical and clinical observations.
To begin with, we developed atezolizumab radiolabeled with indium 111 ( Encouraged by those results, we pursued the development of a PD-L1-targeting positron emission tomography (PET) imaging agent. PET is one of the most sensitive high-resolution imaging technologies used for quantitative imaging of target expression in tumors. PET imaging agents providing real-time quantitation of target expression relevant to immunotherapy can be useful for guiding and monitoring therapy. To develop PD-L1-targeting PET tracer, we conjugated atezolizumab with 2,2 0 ,2 00 -(10-(2,6-dioxotetrahydro-2H-pyran-3-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (DOTAGA anhydrate), and radiolabeled with copper-64 to prepare [ 64 Cu]atezolizumab.
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The PD-L1 specificity of [ Apart from the above described published studies conducted in primary tumors, we also tested the feasibility of PD-L1 PET with [
64 Cu]atezolizumab in a breast cancer lung metastasis model. To mimic the discrete lung metastases observed with breast cancers, we injected MDAMB231 cells that stably expressed firefly luciferase (MDAMB231-luc) into lungs and used [
64 Cu]atezolizumab to detect PD-L1 expression in the metastatic lesions ( Figure 2 ). As demonstrated in Figure 2A Taken together, our studies in different tumor models with variable PD-L1 expression in immunocompromised or immunocompetent mice, and in a metastatic model demonstrated the potential of [ 64 Cu]atezolizumab PET for noninvasive detection of PD-L1 in tumors and metastases. Biodistribution of this human and mouse cross-reactive antibody is also complementary to the reports by other groups on PD-L1 imaging using murine PD-L1-reactive antibodies. [12] [13] [14] 15 One of the interesting observations is the antibody uptake in brown fat, an immunologically relevant tissue, in preclinical models.
Atezolizumab is in different phases of clinical trials for the treatment of NSCLC (NCT03014648, NCT02848651, and NCT02927301), advanced or metastatic urothelial bladder cancer (NCT02951767, NCT02108652), gynecological cancers (NCT03073525), Hodgkin lymphoma (NCT03120676), colorectal cancer (NCT02982694), TNBC (NCT03125902), prostate cancer (NCT02814669), nonclear cell kidney cancer (NCT02724878), and RCC (NCT03024996). [
89 Zr]Atezolizumab imaging in patients showed heterogeneous uptake in tumors between and within patients validating preclinical observations (NCT02453984). 16 Despite increased use of radiolabeled antibodies for imaging tumor-specific biomarkers, desired image contrast and sensitivity require longer clearance times often extending up to days which is impractical for routine clinical use. This prompted us to develop a PET imaging agent that can rapidly detect PD-L1 to capture the dynamic changes in PD-L1 expression in the TME. For this purpose, low-molecularweight peptide-based PET tracers are preferred candidates for clinical applications due to faster clearance and synthetic tractability. PD-L1 binding peptides have recently been reported, 17 although potential of those peptides to detect PD-L1 expression in vivo has not been demonstrated. We selected the peptide WL12 (or 1246) 17 that possessed high binding affinity to PD-L1 and has an ornithine residue that could be selectively modified to obtain a radiotracer while retaining affinity to PD-L1. 18 (Figure 3 ). This rapid and specific detection of tumor PD-L1 expression by [
64 Cu]WL12 PET fits well within the clinical work flow of imaging within 60 minutes of tracer administration.
In summary, we developed PD-L1-specific nuclear and optical imaging agents using a clinically relevant therapeutic antibody. We also developed a peptide-based PET imaging agent with improved sensitivity for rapid detection of PD-L1 in tumors. Rapid and noninvasive detection of PD-L1 expression in various cancers could potentially aid in therapy guidance. These developments create the opportunity to utilize imaging biomarker-driven approaches of patient management and appropriate modulation of immunotherapy to achieve best clinical outcomes.
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